AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01813279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the cell therapy
Description: the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
Study NCT01141608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity High Dose Exercise
Description: Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
Study NCT01141608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
Study NCT01276834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: comparison of everolimus-based and CNI-based immunosuppression
Study NCT01276834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: comparison of everolimus-based and CNI-based immunosuppression
Study NCT03261193 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ITM + Sham QLB
Description: Sham subcutaneous non-anesthetic infiltration with saline
Study NCT03261193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITM + Bupivacaine QLB
Description: QL plane block with local anesthesia
Study NCT03504553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noise reduction
Description: All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
Study NCT00080262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
Study NCT03907345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
Study NCT04311957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of boosted PI
Description: Continuation of the same second-line regimen taken prior to entry:~LPVr 400 mg/100 mg BID or ATVr 300 mg/100 mg QD + 2 NRTIs
Study NCT04650139 — intervention group
Intervention type: PROCEDURE
Intervention: PCI - percutaneous coronary intervention
Description: percutaneous coronary intervention
Study NCT02075073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB3
Study NCT02075073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Herceptin®
Study NCT04311957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Single-tablet, fixed dose combination of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily.
Study NCT04055870 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-guided liver biopsy at MDMC
Description: Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
Study NCT03534219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EarPopper
Description: The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
Study NCT02603900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
Study NCT02603900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine
Description: 20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
Study NCT02603900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Adductor Canal Catheter
Description: Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
Study NCT02603900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter
Description: Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
Study NCT02837159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application
Description: Dietary and physical activity recommendations trough a mobile application
Study NCT03349307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)
Description: Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
Study NCT04377659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive Tocilizumab 8 mg/kg i.v. at enrollment. Dose will be capped at 800 mg per infusion. If there is no improvement or toxicity, a second dose can be given 24 hrs to 5 days later.
Study NCT02538991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulkamid
Description: Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation.
Study NCT02538991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension-free Vaginal Tape
Description: TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
Study NCT03024567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt
Description: 10 capsules daily for 14 days
Study NCT03024567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 capsules daily for 14 days
Study NCT02753881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: whole liver lobe cTACE doxorubicin
Description: Doxorubicin CTACE administered in a whole liver lobe manner.
Study NCT02753881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: superselective cTACE doxorubicin
Description: Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
Study NCT00506675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 42 hours per week of patching
Study NCT00506675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: daily atropine (1%)
Study NCT00506675 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: two hours of daily patching for 4 weeks, then no treatment
Study NCT00506675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: once weekly atropine for 4 weeks, then no treatment
Study NCT02763618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
Study NCT02763618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Neurofeedback training
Description: The placebo training will be a previously recorded Neurofeedback session of a participant in group A
Study NCT02574091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% icotinib hydrochloride cream
Description: Topical administration for twice daily
Study NCT02574091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% icotinib hydrochloride cream
Description: Topical administration for twice daily.
Study NCT04390828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery Meditation
Description: the guided image meditation invention program of the intervention measures of this study include four important elements: 1) Meditation exercises: the exercises to adjust the body and mind through specific attention, so that people gradually feel the state of relaxation through practice; (2) Guided image: the simple visualization and use of mental images produced by imagination as a form of psychotherapy, images come from natural scenes (e.g., forests and mountains, streams and oceans), positive feelings and emotions are generated through psychological imagination to induce psychological and physiological relaxation state; (3) Music aids: reaching a relaxed state with comfortable and slow background music; (4) Breathing relaxation training: the patient is taught to take abdominal breathing to divert attention and stimulate the parasympathetic nervous system to achieve muscle relaxation. The entire intervention process takes about 15 to 20 minutes, 2 times a day.
Study NCT00392639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of 2 cooling procedures
Description: Comparison of 2 cooling procedures
Study NCT00185523 — intervention group
Intervention type: PROCEDURE
Intervention: Allogeneic hematopoietic cell transplantation
Study NCT02574091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily.
Study NCT02075073 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US sourced Herceptin®
Study NCT00501839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 Inhalation Powder NDPI
Description: Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhalation Powder NDPI
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Inhalation Powder ACCUHALER/DISKUS
Description: Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol as needed
Description: Salbutamol inhalation powder
Study NCT01706328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol as needed
Description: Salbutamol inhalation powder
Study NCT02790177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Study NCT02790177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NORMAL SALINE
Study NCT02110251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Therapy
Study NCT02850835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Decision Aid
Description: A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
Study NCT06443827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Sulfate
Description: intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
Study NCT03798314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03798314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT02078258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
Study NCT02078258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABMT
Description: During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
Study NCT01822444 — intervention group
Intervention type: OTHER
Intervention: Biomarker analysis
Study NCT02279953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg
Study NCT02279953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02279953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: escitalopram, citalopram or sertraline
Study NCT01416571 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Description: Intramuscular (IM), two doses
Study NCT01580956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VARIABLE-PSV ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.
Study NCT01580956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STANDARD-PSV ventilatory mode
Description: The two ventilatory modes will be studied during 24h in intubated patients in random order.
Study NCT01998503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Study NCT01998503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally
Study NCT01998503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneous
Study NCT01998503 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given subcutaneous
Study NCT01998503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation (ASCT)
Description: Given on day 0
Study NCT01998503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation (ASCT)
Description: Given on day 0
Study NCT01998503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT01998503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Study NCT05437965 — intervention group
Intervention type: DRUG
Intervention: glucocorticoid and immunosuppressants
Description: This study will include patients with isolated coronary arteritis, whose condition could not be controlled by current clinical treatment. After Multiple Disciplinary Team consultation, these patients may be given glucocorticoid and immunosuppressants.
Study NCT02779036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task-oriented home exercise
Description: Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
Study NCT02779036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Physiotherapy Care
Description: Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
Study NCT00661505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120, 200 or 360 micrograms iv every 4 weeks (starting dose)
Study NCT00278694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT00278694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Study NCT00278694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT00278694 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Study NCT00278694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic surgery
Study NCT00278694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant oxaliplatin
Study NCT01151813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline, oral target dose of 1.0 mg BID, one week titration.
Study NCT01151813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02765321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle promotion
Description: Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
Study NCT00284102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
Study NCT05283681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via Prefilled Syringe (PFS)
Study NCT05283681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection via Auto-Injector (AI)
Study NCT04448665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microbiological investigation
Description: a microbiological tests, including isolation of the pathogen and analysis of their susceptibility/resistance to antimicrobial agents
Study NCT03893786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab.
Study NCT02005107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine IR and Venlafaxine XR
Study NCT02005107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine IR and Venlafaxine XR
Study NCT03052686 — intervention group
Intervention type: OTHER
Intervention: Childbirth with uterine rupture
Description: No intervention. Follow-up of women with rupture uterine at the childbirth.
Study NCT03786640 — intervention group
Intervention type: RADIATION
Intervention: 3T MRI scan
Description: A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.